Follicular Lymphoma - Pipeline Review, H2 2015

Follicular Lymphoma - Pipeline Review, H2 2015

Dec 2015 Global Markets Direct Lymphoma478 Pages Price :
$ 2000
Follicular Lymphoma - Pipeline Review, H2 2015

Summary

Global Markets Directs, Follicular Lymphoma - Pipeline Review, H2 2015, provides an overview of the Follicular Lymphomas therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Follicular Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Follicular Lymphoma and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Follicular Lymphoma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Follicular Lymphoma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Follicular Lymphoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Follicular Lymphoma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Follicular Lymphoma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Follicular Lymphoma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Follicular Lymphoma Overview 10
Therapeutics Development 11
Pipeline Products for Follicular Lymphoma - Overview 11
Pipeline Products for Follicular Lymphoma - Comparative Analysis 12
Follicular Lymphoma - Therapeutics under Development by Companies 13
Follicular Lymphoma - Therapeutics under Investigation by Universities/Institutes 18
Follicular Lymphoma - Pipeline Products Glance 19
Late Stage Products 19
Clinical Stage Products 20
Early Stage Products 21
Follicular Lymphoma - Products under Development by Companies 22
Follicular Lymphoma - Products under Investigation by Universities/Institutes 28
Follicular Lymphoma - Companies Involved in Therapeutics Development 29
AbbVie Inc. 29
Affimed Therapeutics AG 30
AmpliMed Corporation (Inactive) 31
Bayer AG 32
BeiGene(Beijing) Co.,Ltd 33
Bio-Path Holdings, Inc. 34
Biocon Limited 35
Biogenomics Limited 36
Biothera, Inc. 37
Boehringer Ingelheim GmbH 38
Bristol-Myers Squibb Company 39
Celgene Corporation 40
Celltrion, Inc. 41
Cellular Biomedicine Group, Inc. 42
Coherus BioSciences, Inc. 43
CTI BioPharma Corp. 44
Curis, Inc. 45
Dynavax Technologies Corporation 46
Eisai Co., Ltd. 47
EpiZyme, Inc. 48
F. Hoffmann-La Roche Ltd. 49
Genentech, Inc. 50
Gilead Sciences, Inc. 51
GlaxoSmithKline Plc 52
Hutchison MediPharma Limited 53
ImmunoGen, Inc. 54
Immunomedics, Inc. 55
Infinity Pharmaceuticals, Inc. 56
Johnson & Johnson 57
Karyopharm Therapeutics, Inc. 58
Kite Pharma, Inc. 59
Les Laboratoires Servier SAS 60
MedImmune, LLC 61
Medivation, Inc. 62
Merck & Co., Inc. 63
Millennium Pharmaceuticals, Inc. 64
Mirati Therapeutics Inc. 65
MorphoSys AG 66
Nordic Nanovector ASA 67
Novartis AG 68
Ono Pharmaceutical Co., Ltd. 69
Pfizer Inc. 70
Pharmacyclics, Inc. 71
Portola Pharmaceuticals, Inc. 72
ProNAi Therapeutics, Inc. 73
Sandoz International GmbH 74
Seattle Genetics, Inc. 75
TG Therapeutics, Inc. 76
Follicular Lymphoma - Therapeutics Assessment 77
Assessment by Monotherapy Products 77
Assessment by Combination Products 78
Assessment by Target 79
Assessment by Mechanism of Action 84
Assessment by Route of Administration 88
Assessment by Molecule Type 90
Drug Profiles 92
abexinostat hydrochloride - Drug Profile 92
acalabrutinib - Drug Profile 95
AFM-11 - Drug Profile 98
alisertib - Drug Profile 99
ASN-002 - Drug Profile 103
atezolizumab - Drug Profile 104
azacitidine - Drug Profile 108
Betalutin - Drug Profile 112
BGB-3111 - Drug Profile 114
bortezomib - Drug Profile 115
BP-100102 - Drug Profile 121
buparlisib hydrochloride - Drug Profile 122
BVX-20 - Drug Profile 126
CBM-C19.1 - Drug Profile 127
CBM-C20.1 - Drug Profile 128
Cellular Immunotherapy to Target CD22 for B-Cell Leukemia and Lymphoma - Drug Profile 130
Cellular Immunotherapy to Target GM-CSF for Oncology - Drug Profile 132
cerdulatinib - Drug Profile 134
copanlisib hydrochloride - Drug Profile 136
CUDC-907 - Drug Profile 140
daratumumab - Drug Profile 142
dasiprotimut-T - Drug Profile 146
denintuzumab mafodotin - Drug Profile 148
duvelisib - Drug Profile 149
E-7449 - Drug Profile 152
entospletinib - Drug Profile 153
epratuzumab - Drug Profile 154
GS-9901 - Drug Profile 159
GSK-2816126 - Drug Profile 160
HMPL-523 - Drug Profile 161
ibrutinib - Drug Profile 162
ibrutinib + ublituximab + TGR-1202 - Drug Profile 169
idelalisib - Drug Profile 170
IGN-002 - Drug Profile 173
imexon - Drug Profile 174
IMGN-529 - Drug Profile 176
IMMU-114 - Drug Profile 178
Imprime PGG - Drug Profile 179
inebilizumab - Drug Profile 184
inebilizumab + MEDI-0680 - Drug Profile 186
inebilizumab + rituximab - Drug Profile 187
interferon alfa-2b - Drug Profile 188
interferon alfa-2b - Drug Profile 189
ixazomib citrate - Drug Profile 190
JNJ-64052781 - Drug Profile 194
KTEC-19 - Drug Profile 195
lenalidomide - Drug Profile 197
mocetinostat - Drug Profile 202
Monoclonal Antibody Conjugated to Target CD22 for Hematological Cancers - Drug Profile 205
MOR-208 - Drug Profile 206
nivolumab - Drug Profile 208
obinutuzumab - Drug Profile 216
Oncoquest - Drug Profile 219
pembrolizumab - Drug Profile 221
pidilizumab - Drug Profile 230
pixantrone dimaleate - Drug Profile 232
PNT-2258 - Drug Profile 236
polatuzumab vedotin - Drug Profile 238
rituximab biosimilar - Drug Profile 240
rituximab biosimilar - Drug Profile 242
rituximab biosimilar - Drug Profile 243
rituximab biosimilar - Drug Profile 244
rituximab biosimilar - Drug Profile 245
rituximab biosimilar - Drug Profile 246
rituximab biosimilar - Drug Profile 247
S-055746 - Drug Profile 248
SD-101 - Drug Profile 249
selinexor - Drug Profile 251
SGN-CD70A - Drug Profile 257
SH-7129 - Drug Profile 258
tazemetostat - Drug Profile 260
temsirolimus - Drug Profile 262
TGR-1202 - Drug Profile 264
tisagenlecleucel-T - Drug Profile 266
ublituximab + TGR-1202 - Drug Profile 269
ulocuplumab - Drug Profile 270
urelumab - Drug Profile 272
Vaccine for Follicular Lymphoma - Drug Profile 274
Vaccine for Multiple Myeloma and Follicular Lymphoma - Drug Profile 275
venetoclax - Drug Profile 276
vorinostat - Drug Profile 279
Follicular Lymphoma - Recent Pipeline Updates 283
Follicular Lymphoma - Dormant Projects 459
Follicular Lymphoma - Discontinued Products 461
Follicular Lymphoma - Product Development Milestones 462
Featured News & Press Releases 462
Appendix 471
Methodology 471
Coverage 471
Secondary Research 471
Primary Research 471
Expert Panel Validation 471
Contact Us 471
Disclaimer 472

List of Tables
Number of Products under Development for Follicular Lymphoma, H2 2015 17
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2015 18
Number of Products under Development by Companies, H2 2015 20
Number of Products under Development by Companies, H2 2015 (Contd..1) 21
Number of Products under Development by Companies, H2 2015 (Contd..2) 22
Number of Products under Development by Companies, H2 2015 (Contd..3) 23
Number of Products under Investigation by Universities/Institutes, H2 2015 24
Comparative Analysis by Late Stage Development, H2 2015 25
Comparative Analysis by Clinical Stage Development, H2 2015 26
Comparative Analysis by Early Stage Development, H2 2015 27
Products under Development by Companies, H2 2015 28
Products under Development by Companies, H2 2015 (Contd..1) 29
Products under Development by Companies, H2 2015 (Contd..2) 30
Products under Development by Companies, H2 2015 (Contd..3) 31
Products under Development by Companies, H2 2015 (Contd..4) 32
Products under Development by Companies, H2 2015 (Contd..5) 33
Products under Investigation by Universities/Institutes, H2 2015 34
Follicular Lymphoma - Pipeline by AbbVie Inc., H2 2015 35
Follicular Lymphoma - Pipeline by Affimed Therapeutics AG, H2 2015 36
Follicular Lymphoma - Pipeline by AmpliMed Corporation (Inactive), H2 2015 37
Follicular Lymphoma - Pipeline by Bayer AG, H2 2015 38
Follicular Lymphoma - Pipeline by BeiGene(Beijing) Co.,Ltd, H2 2015 39
Follicular Lymphoma - Pipeline by Bio-Path Holdings, Inc., H2 2015 40
Follicular Lymphoma - Pipeline by Biocon Limited, H2 2015 41
Follicular Lymphoma - Pipeline by Biogenomics Limited, H2 2015 42
Follicular Lymphoma - Pipeline by Biothera, Inc., H2 2015 43
Follicular Lymphoma - Pipeline by Boehringer Ingelheim GmbH, H2 2015 44
Follicular Lymphoma - Pipeline by Bristol-Myers Squibb Company, H2 2015 45
Follicular Lymphoma - Pipeline by Celgene Corporation, H2 2015 46
Follicular Lymphoma - Pipeline by Celltrion, Inc., H2 2015 47
Follicular Lymphoma - Pipeline by Cellular Biomedicine Group, Inc., H2 2015 48
Follicular Lymphoma - Pipeline by Coherus BioSciences, Inc., H2 2015 49
Follicular Lymphoma - Pipeline by CTI BioPharma Corp., H2 2015 50
Follicular Lymphoma - Pipeline by Curis, Inc., H2 2015 51
Follicular Lymphoma - Pipeline by Dynavax Technologies Corporation, H2 2015 52
Follicular Lymphoma - Pipeline by Eisai Co., Ltd., H2 2015 53
Follicular Lymphoma - Pipeline by EpiZyme, Inc., H2 2015 54
Follicular Lymphoma - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 55
Follicular Lymphoma - Pipeline by Genentech, Inc., H2 2015 56
Follicular Lymphoma - Pipeline by Gilead Sciences, Inc., H2 2015 57
Follicular Lymphoma - Pipeline by GlaxoSmithKline Plc, H2 2015 58
Follicular Lymphoma - Pipeline by Hutchison MediPharma Limited, H2 2015 59
Follicular Lymphoma - Pipeline by ImmunoGen, Inc., H2 2015 60
Follicular Lymphoma - Pipeline by Immunomedics, Inc., H2 2015 61
Follicular Lymphoma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 62
Follicular Lymphoma - Pipeline by Johnson & Johnson, H2 2015 63
Follicular Lymphoma - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 64
Follicular Lymphoma - Pipeline by Kite Pharma, Inc., H2 2015 65
Follicular Lymphoma - Pipeline by Les Laboratoires Servier SAS, H2 2015 66
Follicular Lymphoma - Pipeline by MedImmune, LLC, H2 2015 67
Follicular Lymphoma - Pipeline by Medivation, Inc., H2 2015 68
Follicular Lymphoma - Pipeline by Merck & Co., Inc., H2 2015 69
Follicular Lymphoma - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 70
Follicular Lymphoma - Pipeline by Mirati Therapeutics Inc., H2 2015 71
Follicular Lymphoma - Pipeline by MorphoSys AG, H2 2015 72
Follicular Lymphoma - Pipeline by Nordic Nanovector ASA, H2 2015 73
Follicular Lymphoma - Pipeline by Novartis AG, H2 2015 74
Follicular Lymphoma - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2015 75
Follicular Lymphoma - Pipeline by Pfizer Inc., H2 2015 76
Follicular Lymphoma - Pipeline by Pharmacyclics, Inc., H2 2015 77
Follicular Lymphoma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 78
Follicular Lymphoma - Pipeline by ProNAi Therapeutics, Inc., H2 2015 79
Follicular Lymphoma - Pipeline by Sandoz International GmbH, H2 2015 80
Follicular Lymphoma - Pipeline by Seattle Genetics, Inc., H2 2015 81
Follicular Lymphoma - Pipeline by TG Therapeutics, Inc., H2 2015 82
Assessment by Monotherapy Products, H2 2015 83
Assessment by Combination Products, H2 2015 84
Number of Products by Stage and Target, H2 2015 86
Number of Products by Stage and Mechanism of Action, H2 2015 91
Number of Products by Stage and Route of Administration, H2 2015 95
Number of Products by Stage and Molecule Type, H2 2015 97
Follicular Lymphoma Therapeutics - Recent Pipeline Updates, H2 2015 289
Follicular Lymphoma - Dormant Projects, H2 2015 465
Follicular Lymphoma - Dormant Projects (Contd..1), H2 2015 466
Follicular Lymphoma - Discontinued Products, H2 2015 467

List of Figures
Number of Products under Development for Follicular Lymphoma, H2 2015 17
Number of Products under Development for Follicular Lymphoma - Comparative Analysis, H2 2015 18
Number of Products under Development by Companies, H2 2015 19
Comparative Analysis by Late Stage Development, H2 2015 25
Comparative Analysis by Clinical Stage Development, H2 2015 26
Comparative Analysis by Early Stage Products, H2 2015 27
Assessment by Monotherapy Products, H2 2015 83
Assessment by Combination Products, H2 2015 84
Number of Products by Top 10 Targets, H2 2015 85
Number of Products by Stage and Top 10 Targets, H2 2015 85
Number of Products by Top 10 Mechanism of Actions, H2 2015 90
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 90
Number of Products by Routes of Administration, H2 2015 94
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 94
Number of Products by Molecule Types, H2 2015 96
Number of Products by Stage and Molecule Types, H2 2015 96

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Country :
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 2000
$ 4000

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top